Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Moves To Launch Free Trade Agreement With EU While Similar Pact With U.S. Remains Stalled

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's free trade agreement with the European Union seems to be moving quickly toward implementation and is likely to take effect before a similar pact between Korea and the U.S

You may also be interested in...



Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits

SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4

Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits

SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4

Korea And U.S. Health Ministers Agree To Enhance Cooperation In Anticipation Of Increased Pharma, Device Trade

SEOUL - South Korea and the U.S. have agreed to strengthen their relationship in the healthcare sector through personnel and information exchanges on food and drug regulations, but an official at South Korea's Ministry of Health and Welfare denied Korean media reports that the countries formalized the agreement with a memorandum of understanding

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel